TriCelX Receives FDA Study May Proceed Letter for XytriX™
The FDA has issued a Study May Proceed letter for TriCelX's Phase 1/2 IND application for XytriX™, authorizing the commencement of the clinical trial. FRISCO, TX, UNITED STATES, April 23, 2026 /EINPresswire.com/ -- TriCelX, Inc. (“ …